For patients with non-small cell lung cancer, tissue samples for testing are usually obtained by small biopsies. The standard of care for all patients with non-small cell lung cancer is to evaluate for >10 biomarkers so oncologists can recommend targeted, personalized therapies.
This study investigated 1757 colorectal cancer (CRC) specimens that received comprehensive genomic and immune profiling, and identified that Early-onset CRC (patient age ≤ 50y) had lower tumor mutational burden (TMB) and reduced immunogenicity compared to late-onset CRC (patient age > 50y).
Following the FDA's approval of trastuzumab deruxtecan (T-DXd) for advanced HER2-low breast cancer, there's debate on whether HER2-low should be a distinct clinical category or just a biomarker for specific treatments.
Optimal treatment of breast cancer is increasingly dependent on genomic profiling, with several recent approvals of therapies targeting specific genomic alterations.
Identification of biomarkers indicative of treatment response is critical for making informed decisions about whether to combine immunotherapy with chemotherapy for more effective cancer management.
We analyzed LAG-3 transcriptomic expression among 514 patients with diverse cancers, including 489 patients with clinical annotation for their advanced malignancies. LAG-3 is highly variable both across and within tumor types, and weakly correlated with other checkpoints like PD-L1, PD-1, and CTLA-4.
The use of immune checkpoint inhibitors (ICI) in patients with bladder cancer (BC) is currently limited. Patients with BC who have experienced loss of the Y chromosome (LOY) often exhibit an aggressive cancer phenotype. In these LOY BC cases, CD8+ T cell exhaustion hampers the development of a robust anti-tumor response.